Skip to main content

Syneos Health, Inc.

SYNHDelisted Sep 28, 2023
Industry
Services-Commercial Physical & Biological Research
SEC CIK
0001610950

Syneos Health, Inc. was delisted on Sep 28, 2023; its insiders filed their last Form 4 on Sep 28, 2023; 317 institutions reported holding it in 13F filings for Q2 2023, worth $4.32B in total; superinvestors Elliott Investment Management and Southeastern Asset Management (Longleaf) held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:42 PM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Syneos Health, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedJan 9, 2023Feb 17, 2022Jan 13, 2021Jan 15, 2020Mar 18, 2019
Revenue$5.39B$5.21B$4.42B$4.68B$4.39B
Cost of revenue$4.14B$3.99B$3.40B––
Selling, general and administrative$547.3M$570.8M$442.5M$446.3M$406.3M
Operating income$403.2M$389.3M$293.1M$237.8M$160.2M
Interest expense$82.4M$79.3M$91.1M$129.8M$130.7M
Income tax$48.1M$80.3M$10.9M-$29.5M$33.0M
Net income$266.5M$234.8M$192.8M$131.3M$24.3M
EPS, basic$2.59$2.26$1.85$1.27$0.23
EPS, diluted$2.58$2.24$1.83$1.25$0.23
Weighted shares, basic103.0M103.9M104.2M103.6M103.4M
Weighted shares, diluted103.5M105.1M105.5M105.0M104.7M
Margins and growth
Operating margin7.5%7.5%6.6%5.1%3.6%
Net margin4.9%4.5%4.4%2.8%0.6%
Revenue growth, year over year+3.5%+18.1%−5.6%+6.5%+64.3%
Net income growth, year over year+13.5%+21.8%+46.9%+440.5%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Syneos Health, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedJan 9, 2023Feb 17, 2022Jan 13, 2021Jan 15, 2020Mar 18, 2019
Cash and equivalents––––$153.9M
Accounts receivable–––$782.3M$728.6M
Total current assets$1.94B$1.77B$1.74B$1.56B$1.49B
Property, plant and equipment$264.3M$222.7M$216.2M$203.9M$183.5M
Goodwill$4.90B$4.96B$4.78B$4.35B$4.33B
Intangible assets$680.9M$854.1M$933.5M$973.1M$1.13B
Total assets$8.20B$8.24B$8.06B$7.45B$7.25B
Accounts payable$118.6M$107.5M$113.7M$136.7M$98.6M
Short-term debt–––$58.1M$50.1M
Total current liabilities$1.72B$1.65B$1.58B$1.52B$1.50B
Long-term debt$2.61B$2.78B$2.90B$2.55B$2.74B
Total liabilities$4.70B$4.82B$4.82B$4.42B$4.40B
Shareholders' equity$3.50B$3.41B$3.24B$3.03B$2.86B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Syneos Health, Inc., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedJan 9, 2023Feb 17, 2022Jan 13, 2021Jan 15, 2020Mar 18, 2019
Operating cash flow$427.0M$450.3M$425.5M$318.5M$303.4M
Capital expenditures$93.5M$56.8M$50.0M$64.0M$54.6M
Free cash flow$333.5M$393.4M$375.5M$254.5M$248.9M
Depreciation and amortization$247.2M$235.6M$222.4M$242.5M$273.7M
Stock-based compensation$57.3M$65.2M$58.5M$55.2M$34.3M
Share buybacks$150.0M$117.5M$70.2M$56.7M$75.0M
Investing cash flow-$105.6M-$340.3M-$504.1M-$81.7M-$145.5M
Financing cash flow-$339.2M-$277.6M$178.3M-$215.5M-$319.4M
Net change in cash$5.53M-$165.7M$108.5M$7.76M-$166.0M
Ratio
Stock-based compensation, % of revenue1.1%1.3%1.3%1.2%0.8%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Syneos Health, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Jul 31, 2023103.7M+1.0%SEC
May 2, 2023103.6M+1.0%SEC
Feb 9, 2023103.2M−0.9%SEC
Oct 31, 2022102.9M−0.8%SEC
Jul 27, 2022102.7M−0.8%SEC
Apr 21, 2022102.6M−1.6%SEC
Feb 10, 2022104.2M−0.1%SEC
Oct 27, 2021103.7M−0.3%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.